PT Darya-Varia Laboratoria TBK (Darya-Varia) relaunched D-STAR 2025 (Darya-Varia Scholarship for Talented and Aspiring Women Researchers) this year. The scholarship program is exclusively designated to support talented women pharmacy students. In 2025, D-STAR emphasizes herbal research utilizing Indonesia’s natural resources, a field with great potential.

PT Darya-Varia Laboratoria Tbk (“Darya-Varia”) has officially entered into a strategic partnership with PT Eisai Indonesia (“EISAI”) in the gastrointestinal therapy segment, as part of a shared commitment to expanding patient access to innovative, high-quality, and clinically proven healthcare solutions.

BOGOR, 25 July 2025 – PT Darya-Varia Laboratoria Tbk (“Darya-Varia” or “the Company”) carried out a corporate social responsibility (CSR) program titled Generasi Sehat, Komunitas Berdaya (“Healthy Generation, Empowered Community”) in two villages in Bogor Regency: Cibatok 1 and Cibatok 2. 

Jakarta, 18 June 2025 – PT Darya-Varia Laboratoria Tbk (Darya-Varia or the Company) successfully held its Annual General Meeting of Shareholders (AGMS) this morning, June 18, 2025, at The St. Regis Jakarta Hotel. During the AGMS, the Company reported that Darya-Varia continues to demonstrate resilience and consistency amid global economic challenges and ongoing changes in the pharmaceutical industry. 

Darya-Varia in collaboration with PT Astra Komponen Indonesia (ASKI), a subsidiary of PT Astra Otoparts Tbk, has signed a Memorandum of Understanding (MoU) for a Strategic Partnership aimed at developing and manufacturing local medical devices, thereby strengthening Darya-Varia's position in the Indonesian healthcare industry.

PT Darya-Varia Laboratoria Tbk, one of the leading pharmaceutical companies in Indonesia, announced the  D-STAR scholarship program (Darya-Varia Scholarship for Talented and Aspiring Researchers) which is aimed at female students majoring in pharmacy who have an interest and talent in study. 

Jakarta, June 11, 2024 – In a dynamic market environment in 2023, Darya-Varia has showcased notable resilience and strategic prowess, primarily driven by the robust performance of its prescription business. The Company’s net revenues from its prescription business in 2023 managed to surpass the target set at the beginning of the year, with a growth of 11% from the 2022 result, well above the growth of the prescription drug market in Indonesia which stood at 4%.

Jakarta, 9 Desember 2023 - Sebagai perusahaan farmasi dengan pengalaman selama lebih dari 47 tahun di Indonesia, Darya-Varia terus berkomitmen untuk memperkuat misinya dalam meningkatkan kualitas kesehatan masyarakat. Langkah ini diwujudkan melalui produk baru HerbaBlend Cough & Flu yang mulai diperkenalkan pada 1 Desember 2023.

JAKARTA - The government continues to ensure halal products within the country through the implementation of halal certification requirements. One of the ongoing efforts is to encourage small and medium-sized enterprises (SMEs) to understand the Halal Product Assurance System (SJPH).

SJPH is a standard developed with the aim of ensuring the quality and halal status of products. When implemented correctly, businesses can maintain the quality of their products.

PT Darya-Varia Laboratoria Tbk, in collaboration with APP Jakarta Polytechnic and the Ministry of Industry, was embarking on an innovative effort to enhance halal literacy among Small and Medium Enterprises (SMEs) through the "Halalpreneur" program, which focuses on halal certification through a Business Incubator Unit. This synergy between the private sector and the government is a joint commitment to strengthen understanding of the importance of halal certification in the industry.

JAKARTA – PT Darya-Varia Laboratoria Tbk mampu mencetak pertumbuhan kinerja keuangan yang solid. Hal itu terlihat dari laba bersih perseroan pada 2018 melonjak 23,7% menjadi Rp 200,7 miliar dibanding tahun sebelumnya.